Quoin Pharmaceuticals, Ltd. (QNRX): Results of Operations and Financial Condition
Quoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Com
How this was made
The 30-second read
Why it matters
The most tradable elements are the FDA conditional brand-name approval for QRX003 (QYLEKI), IND submission and subsequent FDA clearance for Peeling Skin Syndrome enabling a Phase 2/3 start in 2H 2026, and a USPTO Notice of Allowance for a combination-treatment patent. Together these reduce certain regulatory friction points and can improve probability-weighted valuation for the lead asset(s).
Market read
Regulatory and IP milestones plus a stated cash runway into 2027 provide fresh, company-specific catalysts for QNRX trading, though no new efficacy data is included.
What to watch
Cash runway into 2027 is helpful, but dilution risk and trial enrollment/operational execution for the planned Phase 2/3 in 2H 2026 remain key swing factors.
Quoin Pharmaceuticals reported a second-quarter net loss of $5,371,042 while advancing QRX003 in Netherton Syndrome and Peeling Skin Syndrome and QRX009 toward clinical testing.
The company reported a wider net loss and higher research and development expense, while delivering regulatory and clinical-development progress for QRX003 and outlining additional QRX009 development activity. Cash, cash equivalents and marketable securities were reported at approximately $10.8 million, with operations expected to be funded into 2027.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| General and administrative expense, three months ended June 30, 2026GAAP | $ 1,846,406 | – | – |
| Research and development expense, three months ended June 30, 2026GAAP | $ 3,627,168 | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | $ 5,473,574 | – | – |
| Unrealized (gain) loss, three months ended June 30, 2026GAAP | $ (1,585 ) | – | – |
| Realized and accrued interest income, three months ended June 30, 2026GAAP | $ (100,947 ) | – | – |
| Total other income, three months ended June 30, 2026GAAP | $ (102,532 ) | – | – |
| Net loss, three months ended June 30, 2026GAAP | $ (5,371,042 ) | – | – |
| Foreign currency translation, three months ended June 30, 2026GAAP | (423 ) | – | – |
| Comprehensive loss, three months ended June 30, 2026GAAP | $ (5,371,465 ) | – | – |
| Loss per ADS, basic, three months ended June 30, 2026GAAP | $ (1.90 ) | – | – |
| Loss per ADS, fully-diluted, three months ended June 30, 2026GAAP | $ (1.90 ) | – | – |
| Weighted average number of ADS's outstanding, basic, three months ended June 30, 2026GAAP | 2,832,915 | – | – |
| Weighted average number of ADS's outstanding, fully-diluted, three months ended June 30, 2026GAAP | 2,832,915 | – | – |
| General and administrative expense, six months ended June 30, 2026GAAP | $ 3,543,854 | – | – |
| Research and development expense, six months ended June 30, 2026GAAP | $ 7,060,930 | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | $ 10,604,784 | – | – |
| Unrealized (gain) loss, six months ended June 30, 2026GAAP | $ 11,715 | – | – |
| Realized and accrued interest income, six months ended June 30, 2026GAAP | $ (247,722 ) | – | – |
| Total other income, six months ended June 30, 2026GAAP | $ (236,007 ) | – | – |
| Net loss, six months ended June 30, 2026GAAP | $ (10,368,777 ) | – | – |
| Foreign currency translation, six months ended June 30, 2026GAAP | 31 | – | – |
| Comprehensive loss, six months ended June 30, 2026GAAP | $ (10,368,746 ) | – | – |
| Loss per ADS, basic, six months ended June 30, 2026GAAP | $ (3.66 ) | – | – |
| Loss per ADS, fully-diluted, six months ended June 30, 2026GAAP | $ (3.66 ) | – | – |
| Weighted average number of ADS's outstanding, basic, six months ended June 30, 2026GAAP | 2,831,948 | – | – |
| Weighted average number of ADS's outstanding, fully-diluted, six months ended June 30, 2026GAAP | 2,831,948 | – | – |
second half of 2026 and before the end of 2026 outlook
- NoteThe planned Phase 2/3 study for Peeling Skin Syndrome is expected to initiate in the second half of 2026.
- NoteThe Company plans to submit an IND to the FDA for an additional indication before the end of 2026.
- NoteThe Company believes its current cash position will fund operations into 2027.
What drove it
- The FDA conditionally approved QYLEKI™ as the proposed brand name for QRX003 for Netherton Syndrome on June 23, 2026.
- Quoin reported a positive clinical update from its ongoing Pediatric Compassionate Use Program on June 16, 2026.
- The U.S. Patent and Trademark Office issued a Notice of Allowance on June 30, 2026 for U.S. Patent Application No. 18/428,570, “Combination Treatment for Netherton Syndrome.”
- The FDA cleared Quoin's IND for Peeling Skin Syndrome on July 9, 2026 and expressed no safety concerns regarding study design or duration of dosing.
- QRX009 is advancing toward clinical testing, with investigator-led studies planned in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.
Concerns
- Net loss for the quarter ended June 30, 2026 was approximately $5.4 million, compared to approximately $3.7 million for the quarter ended June 30, 2025.
- Research and development expense for the three months ended June 30, 2026 was $ 3,627,168, compared to $ 2,050,585 for the three months ended June 30, 2025.
- The planned Peeling Skin Syndrome Phase 2/3 study is expected to initiate in the second half of 2026, and the filing describes this timing as forward-looking.
- The Company believes its current cash position will fund operations into 2027.
What to watch
- Initiation of the planned Phase 2/3 study for Peeling Skin Syndrome in the second half of 2026.
- Progress of QRX003 toward pivotal development in Netherton Syndrome.
- Submission of an IND to the FDA for an additional QRX009 indication before the end of 2026.
- Clinical-testing progress for QRX009 across planned investigator-led studies.
- Cash position and operating funding runway into 2027.
Balance sheet and cash flow
- Cash and cash equivalents as of June 30, 2026: $ 3,845,606; December 31, 2025: $ 3,818,096.
- Investments as of June 30, 2026: 6,954,476; December 31, 2025: 14,927,165.
- Prepaid expenses and other current assets as of June 30, 2026: 836,146; December 31, 2025: 1,261,974.
- Total current assets as of June 30, 2026: 11,636,228; December 31, 2025: 20,007,235.
- Intangible assets, net as of June 30, 2026: 333,334; December 31, 2025: 383,334.
- Total assets as of June 30, 2026: $ 11,969,562; December 31, 2025: $ 20,390,569.
- Accounts payable as of June 30, 2026: $ 3,109,517; December 31, 2025: $ 1,262,222.
- Accrued expenses as of June 30, 2026: 1,757,390; December 31, 2025: 2,538,457.
- Accrued interest and financing expense as of June 30, 2026: 1,146,251; December 31, 2025: 1,146,251.
- Due to officers - short term as of June 30, 2026: 600,000; December 31, 2025: 600,000.
- Total current liabilities as of June 30, 2026: 6,613,158; December 31, 2025: 5,546,930.
- Due to officers - long term as of June 30, 2026: 1,423,733; December 31, 2025: 1,723,733.
- Total liabilities as of June 30, 2026: $ 8,036,891; December 31, 2025: $ 7,270,663.
- Ordinary shares issued and outstanding as of June 30, 2026: 70,294,615 (2,008,418 ADS's); December 31, 2025: 52,441,360 (1,498,325 ADS's).
- Accumulated other comprehensive loss as of June 30, 2026: (582 ); December 31, 2025: (613 ).
- Additional paid in capital as of June 30, 2026: 85,272,477; December 31, 2025: 84,090,966.
- Accumulated deficit as of June 30, 2026: (81,339,224 ); December 31, 2025: (70,970,447 ).
- Total shareholders' equity as of June 30, 2026: 3,932,671; December 31, 2025: 13,119,906.
- Total liabilities and shareholders' equity as of June 30, 2026: $ 11,969,562; December 31, 2025: $ 20,390,569.
- The Company had approximately $10.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
Analysis
Quoin reported no revenue in the filing and remained in a development-stage operating profile. GAAP net loss for the three months ended June 30, 2026 was $ (5,371,042 ), compared with $ (3,695,938 ) for the three months ended June 30, 2025. Research and development expense was $ 3,627,168, compared with $ 2,050,585, while general and administrative expense was $ 1,846,406, compared with $ 1,742,594. Total operating expenses were $ 5,473,574, compared with $ 3,793,179.
For the six months ended June 30, 2026, GAAP net loss was $ (10,368,777 ), compared with $ (7,508,117 ) in the prior-year period. Research and development expense was $ 7,060,930, compared with $ 4,424,724, and total operating expenses were $ 10,604,784, compared with $ 7,750,356. Basic and fully-diluted loss per ADS for the quarter were each $ (1.90 ), compared with $ (6.28 ) in the prior-year quarter.
The operational update centered on QRX003. The FDA conditionally approved QYLEKI™ as the proposed brand name for QRX003 for Netherton Syndrome on June 23, 2026. Quoin also reported a positive update from its Pediatric Compassionate Use Program and received a Notice of Allowance for a U.S. patent application covering a combination treatment for Netherton Syndrome. For Peeling Skin Syndrome, the company submitted an IND on June 2, 2026; subsequent to quarter end, the FDA cleared the IND on July 9, 2026 and expressed no safety concerns regarding study design or duration of dosing.
QRX009 remained an earlier-stage platform advancing toward clinical testing, with investigator-led studies planned across Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. The company also plans to submit an IND for an additional indication before the end of 2026. These pipeline activities are the stated drivers of the period, but the planned Peeling Skin Syndrome Phase 2/3 study and QRX009 programs remain prospective clinical milestones.
Quoin reported approximately $10.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026 and stated that its current cash position will fund operations into 2027. The balance sheet showed cash and cash equivalents of $ 3,845,606 and investments of 6,954,476 as of June 30, 2026. Total shareholders' equity was 3,932,671, while total liabilities were $ 8,036,891. The central financial items to monitor are the continuing loss profile, research and development spending, clinical-study initiation, and the stated operating runway.
Management, verbatim
The second quarter was a highly productive period across both of our delivery technology platforms.
Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
Our Ichthyosis focused platform, QRX003 continued to advance toward pivotal development in Netherton Syndrome while expanding into additional rare dermatologic indications, highlighted by FDA clearance of the first-ever formal clinical study for a potential Peeling Skin Syndrome therapy.
Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
With QRX003 approaching Phase 3 and QRX009 advancing toward clinical testing, we believe Quoin has built one of the broadest development pipelines focused exclusively on rare dermatologic diseases.
Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
Not in the filing
stated, not guessed- Revenue
- Revenue by segment
- Gross profit and gross margin
- Operating income or loss as a separately reported line item
- Income tax expense or benefit and tax rate
- Non-GAAP financial metrics
- Operating cash flow
- Free cash flow
- Capital expenditures
- Share repurchases
- Dividends
- Debt as a separately reported debt balance
- Prior-quarter comparisons for statement-of-operations metrics
- Percentage year-over-year and quarter-over-quarter changes
- Prior outlook for guidance comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K (Item 2.02) includes an Exhibit 99.1 corporate update with second-quarter 2026 financial highlights and a series of FDA/USPTO and IND-related pipeline milestones.
Ticker impact
Quoin reports FDA conditional approval of QYLEKI as the brand name for QRX003 in Netherton syndrome and provides multiple regulatory and clinical pipeline updates.
Bias toward positive near-term repricing, with follow-through dependent on Phase 2/3 execution and upcoming IND submissions.
The filing discloses several discrete FDA and USPTO events plus a cash runway statement, which typically matter for late-stage biotech valuation and trading. However, it does not provide new efficacy data or quantified guidance that would fully de-risk timelines.
Market effects
Adds incremental positive signal for rare dermatology development programs and for topical delivery platforms, but without broader sector policy or pricing impact.
Primarily US regulatory-driven; limited direct regional spillover beyond biotech sentiment.
FDA milestones may influence global orphan-disease investor sentiment, but the news is company-specific.
Counterpoint
Despite multiple approvals, the company still reports net losses and no commercial revenue, so the market may discount progress until pivotal Phase 3 outcomes are closer.
Key entities
- issuerQuoin Pharmaceuticals Ltd.
Late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases; subject of the 8-K update.
- product_programQRX003 (QYLEKI™)
Netherton syndrome program; FDA conditionally approved QYLEKI as the proposed brand name and received a USPTO Notice of Allowance for a combination treatment patent.
- product_programQRX003 Peeling Skin Syndrome (PSS)
IND submitted and later cleared by FDA after quarter end, enabling a first company-sponsored Phase 2/3 study expected to initiate in 2H 2026.
- product_programQRX009
Topical rapamycin platform advancing toward clinical testing across multiple investigator-led indications.